SGLT2 inhibitors and lower limb complications: an updated meta‐analysis

Table 2 Meta-regression analysis for the associated factors and risk of amputation events in patients with SGLT2i treatment

Parameter	β	95% CI	P value	Parameter	β	95% CI	P value
Demographic characteristic
Age (year old)	− 0.090	− 0.224, 0.045	0.163	Sex (male%)	0.013	− 0.023, 0.049	0.780
BMI (kg/m²)	0.097	− 0.231, 0.426	0.506	Diabetes duration (year)	0.177	− 0.036, 0.390	0.984
HbA1c and weight change
HbA1c change (%)	0.689	− 4.454, 5.832	0.761	Weight change (kg)*	− 0.461	− 0.726, − 0.197	0.007
HbA1c change difference (%)	− 0.479	− 6.171, 5.213	0.848	Weight change difference (kg)*	− 0.436	− 0.795, − 0.078	0.026
Hemodynamic indicator
Baseline SBP (mmHg)	0.005	− 0.094, 0.105	0.902	Baseline DBP (mmHg)*	− 0.528	− 0.852, − 0.205	0.009
SBP change (mmHg)	− 0.254	− 0.545, 0.037	0.075	DBP change (mmHg)	− 0.279	− 0.638, 0.079	0.096
Volume depletion (event%)	− 0.372	− 0.900, 0.155	0.121	−	−	−	−
Renal function profile
Baseline eGFR (mL/min/1.73m²)	0.058	− 0.393, 0.508	0.352	eGFR change (mL/min/1.73m²)	0.393	− 1.183, 1.969	0.550
PAD risk factor
Previous PAD (%)	0.003	− 0.296, 0.301	0.973	−	−	−	−

*P < 0.05. BMI body mass index, SGLT2i sodium glucose co-transporter 2 inhibitor, PAD peripheral arterial disease, SBP systolic blood pressure, DBP diastolic blood pressure, HCT hematocrit, eGFR estimated glomerular filtration rate

ISSN: 1475-2840